Titles
- Disparities in health and health care: five key questions and answers1
- Dissolution testing and acceptance criteria for immediate-release solid oral dosage form drug products containing high solubility drug substances1
- Drug and device manufacturer communications with payors, formulary committees, and similar entities: questions and answers : guidance for industry and review staff1
- Drug supply chain security: dispensers received most tracing information1
- Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment1
- E11(R1) addendum: clinical investigation of medicinal products in the pediatric population1
- E17 general principles for planning and design of multiregional clinical trials1
- E18 genomic sampling and management of genomic data1
- E6(R2) good clinical practice: integrated addendum to ICH E6(R1)1
- Electronic health record adoption and interoperability among U.S. skilled nursing facilities and home health agencies in 20171
- Elemental impurities in drug products1
- Enforcement policy--OTC sunscreen drug products marketed without an approved application1
- Entities generally met Federal Select Agent Program internal inspection requirements, but CDC could do more to improve effectiveness1
- Entities' experiences and perceptions of reporting the theft, loss, or release of select agents or toxins to CDC1
- Establishing effectiveness for drugs intended to treat male hypogonadotropic hypogonadism attributed to nonstructural disorders1
- Explaining Stewart v. Azar: implications of the court's decision on Kentucky's Medicaid waiver1
- Extension of certain tobacco product compliance deadlines related to the final deeming rule: (revised)1
- FDA should further integrate its review of cybersecurity into the premarket review process for medical devices1
- Facility definition under Section 503B of the Federal Food, Drug, and Cosmetic Act1
- HRSA helped health centers with elevated risks and can continue to take additional steps1